Wellington Management Group LLP Sells 36,866 Shares of Vera Therapeutics, Inc. $VERA

Wellington Management Group LLP trimmed its stake in Vera Therapeutics, Inc. (NASDAQ:VERA) by 61.6% in the second quarter, HoldingsChannel reports. The firm owned 22,990 shares of the company’s stock after selling 36,866 shares during the period. Wellington Management Group LLP’s holdings in Vera Therapeutics were worth $987,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Los Angeles Capital Management LLC acquired a new position in shares of Vera Therapeutics during the fourth quarter valued at about $46,000. Quantbot Technologies LP acquired a new stake in shares of Vera Therapeutics in the 2nd quarter valued at about $51,000. Aster Capital Management DIFC Ltd acquired a new position in Vera Therapeutics during the 4th quarter worth approximately $71,000. Tower Research Capital LLC TRC raised its stake in Vera Therapeutics by 192.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after buying an additional 2,757 shares during the period. Finally, Sandia Investment Management LP bought a new position in Vera Therapeutics in the fourth quarter worth approximately $127,000. 99.21% of the stock is owned by institutional investors.

Vera Therapeutics Stock Performance

Shares of VERA stock opened at $35.05 on Friday. The firm has a 50-day moving average of $35.11 and a 200-day moving average of $37.18. The company has a market cap of $2.53 billion, a P/E ratio of -5.98 and a beta of 0.96. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.92. Vera Therapeutics, Inc. has a one year low of $22.72 and a one year high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Monday, August 10th. The company reported ($1.52) earnings per share for the quarter, topping the consensus estimate of ($1.58) by $0.06. During the same quarter in the previous year, the firm earned ($1.20) EPS. Equities research analysts forecast that Vera Therapeutics, Inc. will post -6.44 EPS for the current fiscal year.

Analyst Ratings Changes

VERA has been the subject of a number of research reports. Evercore set a $91.00 price objective on Vera Therapeutics in a research note on Friday, May 15th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $84.00 target price on shares of Vera Therapeutics in a research report on Tuesday, August 11th. TD Cowen lifted their price target on shares of Vera Therapeutics from $73.00 to $78.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Needham & Company LLC set a $125.00 price target on shares of Vera Therapeutics in a research note on Wednesday, July 8th. Finally, The Goldman Sachs Group restated a “buy” rating and set a $90.00 price target on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Vera Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $80.15.

Insider Buying and Selling

In other Vera Therapeutics news, CEO Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $35.12, for a total transaction of $649,720.00. Following the transaction, the chief executive officer owned 235,244 shares of the company’s stock, valued at $8,261,769.28. This trade represents a 7.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 83,250 shares of company stock valued at $3,307,800. Company insiders own 15.90% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company’s research is centered on therapies designed to address the underlying causes of autoimmune conditions rather than primarily managing their symptoms.

Vera’s leading product candidate is atacicept, an investigational biologic designed to inhibit two proteins involved in the survival and activity of antibody-producing immune cells, B-cell activating factor and a proliferation-inducing ligand.